Zoya Demidenko: Scientist in Tumor Science
Zoya Demidenko is a prominent researcher affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she was employed at the NIH and New York Medical College, building a robust base in biomedical investigation.
Demidenko's scholarly work covers a number of critical areas, including the PI3K/AKT/mTOR molecular pathway, cell cycle control, cellular aging, and cancer biology. To date, she has co-authored more than 46 academic publications, which have accumulated upwards of 4,100 references a indicator to the impact of her findings.
Among her key achievements concerns elucidating the pathways of biological cell aging. Her research demonstrated that when the cellular division cycle is arrested while cellular growth continues, the cells experience senescence. Importantly, Zoya Demidenko demonstrated that this transition is inhibited by medication using substances such as rapamycin.
Zoya Demidenko has furthermore contributed greatly to tumor management investigation, notably in the domain of cyclotherapy a strategy designed to safeguarding healthy tissue from chemotherapy while leaving cancer cells susceptible. This method holds considerable hope for lowering the adverse effects of cancer treatment.
Throughout her scientific life, Demidenko has partnered with prominent investigators globally, including Dr. Mikhail Blagosklonny. Her research can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a influential voice in contemporary oncological research, with her findings continue to influence our knowledge of the way biological cells grow old, interact with therapy, and the ways in which malignant disease may be more effectively targeted.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=